Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Receivables (2016 - 2025)

Ani Pharmaceuticals' Receivables history spans 14 years, with the latest figure at $281.1 million for Q4 2025.

  • For Q4 2025, Receivables rose 26.77% year-over-year to $281.1 million; the TTM value through Dec 2025 reached $281.1 million, up 26.77%, while the annual FY2025 figure was $281.1 million, 26.77% up from the prior year.
  • Receivables for Q4 2025 was $281.1 million at Ani Pharmaceuticals, up from $252.6 million in the prior quarter.
  • Across five years, Receivables topped out at $281.1 million in Q4 2025 and bottomed at $91.9 million in Q1 2021.
  • The 5-year median for Receivables is $171.4 million (2022), against an average of $171.9 million.
  • The largest annual shift saw Receivables skyrocketed 62.35% in 2022 before it fell 4.9% in 2023.
  • A 5-year view of Receivables shows it stood at $128.5 million in 2021, then surged by 32.61% to $170.4 million in 2022, then fell by 4.9% to $162.1 million in 2023, then soared by 36.8% to $221.7 million in 2024, then increased by 26.77% to $281.1 million in 2025.
  • Per Business Quant, the three most recent readings for ANIP's Receivables are $281.1 million (Q4 2025), $252.6 million (Q3 2025), and $225.7 million (Q2 2025).